Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

115.46USD
17 Apr 2014
Price Change (% chg)

$-0.08 (-0.07%)
Prev Close
$115.54
Open
$115.61
Day's High
$117.19
Day's Low
$115.02
Volume
3,237,732
Avg. Vol
3,767,402
52-wk High
$128.96
52-wk Low
$94.15

AMGN.O

Chart for AMGN.O

About

Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the... (more)

Overall

Beta: 0.61
Market Cap (Mil.): $87,344.02
Shares Outstanding (Mil.): 756.49
Dividend: 0.61
Yield (%): 2.11

Financials

  AMGN.O Industry Sector
P/E (TTM): 17.39 33.26 33.35
EPS (TTM): 6.64 -- --
ROI: 9.74 19.66 18.92
ROE: 24.69 20.35 19.68
Search Stocks

Biotech stocks rout beginning to reveal pockets of value

NEW YORK - Predicting when the bear market in biotech stocks will hit bottom is a hazardous prospect, but one gauge that factors in the rapid profit growth estimates for many of these companies suggests several are starting to look attractive.

16 Apr 2014

Amgen melanoma drug fails to improve overall survival rates

- Amgen Inc said its experimental drug to treat a deadly form of skin cancer did not significantly improve overall survival rates in patients enrolled in a late-stage study.

04 Apr 2014

Amgen ends marketing agreement with GSK for osteoporosis drug

- Amgen Inc said it would end an agreement with GlaxoSmithKline Plc for the marketing of its osteoporosis drug in some regions outside the United States.

03 Apr 2014

UPDATE 1-Amgen ends marketing agreement with GSK for osteoporosis drug

April 3 - Amgen Inc said it would end an agreement with GlaxoSmithKline Plc for the marketing of its osteoporosis drug in some regions outside the United States.

03 Apr 2014

Amgen ends marketing agreement with GSK for osteoporosis drug

April 3 - Amgen Inc said it was ending an agreement with GlaxoSmithKline Plc, under which the British company marketed Amgen's postmenopausal osteoporosis drug in some regions outside the United States.

03 Apr 2014

Amgen drug lowers cholesterol up to 66 percent in pivotal studies

WASHINGTON - Amgen Inc's drug from a high profile new class of experimental medicines lowered "bad" LDL cholesterol by 55 percent to 66 percent compared with a placebo in a trio of late-stage clinical trials, according to data presented on Saturday.

29 Mar 2014

Amgen drug lowers cholesterol up to 66 pct in pivotal studies

WASHINGTON, March 29 - Amgen Inc's drug from a high profile new class of experimental medicines lowered "bad" LDL cholesterol by 55 percent to 66 percent compared with a placebo in a trio of late-stage clinical trials, according to data presented on Saturday.

29 Mar 2014

Amgen drug meets goal for those with high genetic cholesterol

- Amgen Inc said its experimental new type of cholesterol-fighting drug met the primary goal of a late-stage trial by slashing "bad" LDL cholesterol levels in patients with a genetic tendency towards high levels of the artery-clogging fat.

17 Mar 2014

UPDATE 2-Amgen drug meets goal for those with high genetic cholesterol

March 17 - Amgen Inc said its experimental new type of cholesterol-fighting drug met the primary goal of a late-stage trial by slashing "bad" LDL cholesterol levels in patients with a genetic tendency towards high levels of the artery-clogging fat.

17 Mar 2014

Amgen drug meets goal for those with high genetic cholesterol

March 17 - Amgen Inc said on Monday its experimental new type of cholesterol fighter met the primary goal of a late-stage trial by significantly cutting "bad" LDL cholesterol among patients with a genetic tendency towards very high levels of the artery clogging fat.

17 Mar 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks